<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugSwotsOutput><SWOTs><SWOT><Class>Anticancer anti-CD20 monoclonal antibodies</Class><Strengths><Strength name="Strength" sortOrder="1">&lt;para&gt;Current market leader in non-Hodgkin&amp;apos;s lymphoma (NHL) and chronic lymphocytic leukemia (CLL); studied extensively with over 3.5 million patients exposures [&lt;ulink linkType="Reference" linkID="1118084"&gt;1118084&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1118085"&gt;1118085&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="2">&lt;para&gt;Strong CLL data, with improvements seen in PFS of 8.3 and 5.0 months in first-line and previously treated CLL, respectively, and improved overall survival in first-line CLL (87% of patients were alive after 3 years on Rituxan plus fludarabine/cyclophosphamide, versus 82% for fludarabine/cyclophosphamide alone) [&lt;ulink linkType="Reference" linkID="1072739"&gt;1072739&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1062708"&gt;1062708&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1058286"&gt;1058286&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="3">&lt;para&gt;Broad label; approved in combination therapy for first-line and previously treated CLL, first-line diffuse large B-cell lymphoma (DLBCL) and follicular NHL, and monotherapy for low-grade NHL following first-line CVP chemotherapy and for relapsed or refractory low-grade or follicular NHL [&lt;ulink linkType="Reference" linkID="1118085"&gt;1118085&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="4">&lt;para&gt;Superior efficacy in PFS and complete response in combination with &lt;ulink linkType="Drug" linkID="47000"&gt;Treanda&lt;/ulink&gt; versus Rituxan plus CHOP in first-line NHL [&lt;ulink linkType="Reference" linkID="1074873"&gt;1074873&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="5">&lt;para&gt;Was the first therapy in over 20 years to increase overall survival for aggressive NHL; improved 5-year overall survival by 58 versus 46% for CHOP in first-line DLBCL, and improved PFS by 104% in low-grade NHL, and by 113% at 2.5-year follow-up in first-line follicular NHL [&lt;ulink linkType="Reference" linkID="601657"&gt;601657&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1118085"&gt;1118085&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="6">&lt;para&gt;Also approved in the maintenance setting for NHL, which was supported by PRIMA data, which showed that at 10 years, 51% of patients remained progression free versus 35% in the control group [&lt;ulink linkType="Reference" linkID="2023081"&gt;2023081&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="7">&lt;para&gt;A subcutaneous formulation has been developed which has a faster 5-min administration time; approval was granted in the EU for DLBCL and FL in March 2014, followed by CLL in May 2016 - US approval for DLBCL, FL and CLL was granted in the US in June 2017 [&lt;ulink linkType="Reference" linkID="1540512"&gt;1540512&lt;/ulink&gt;]&lt;/para&gt;</Strength></Strengths><Weaknesses><Weakness name="Weakness" sortOrder="1">&lt;para&gt;Boxed warning for fatal infusion reactions, severe mucocutaneous reactions, the risk of hepatitis B virus reactivation with fulminant hepatitis and hepatic failure resulting in death and progressive multifocal leukoencephalopathy (PML), including fatal PML [&lt;ulink linkType="Reference" linkID="1118084"&gt;1118084&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1118085"&gt;1118085&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="2">&lt;para&gt;Further warnings on label regarding tumor lysis syndrome, cardiac arrhythmias, angina, severe, including fatal, renal toxicity and serious infections and cytopenias requiring blood count monitoring [&lt;ulink linkType="Reference" linkID="1118084"&gt;1118084&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1118085"&gt;1118085&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="3">&lt;para&gt;Use is associated with abdominal pain, bowel obstruction and perforation, in some cases leading to death [&lt;ulink linkType="Reference" linkID="1118085"&gt;1118085&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="4">&lt;para&gt;Premedication with acetaminophen, corticosteroids and antihistamines is required to prevent infusion reactions; premedication with anti-uricemics is required to prevent tumor lysis syndrome in patients with greater risk, including those with high circulating lymphocyte count or with renal impairment [&lt;ulink linkType="Reference" linkID="1480951"&gt;1480951&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="5">&lt;para&gt;There is some evidence that Rituxan maintenance does not exert an impact on overall survival compared with watchful waiting or first-line Rituxan without maintenance in patients with low-burden follicular lymphoma or indolent asymptomatic follicular lymphoma [&lt;ulink linkType="Reference" linkID="1534000"&gt;1534000&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1623837"&gt;1623837&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="6">&lt;para&gt;Each infusion in CLL and in NHL patients in their first cycle may last 4 to 6 h [&lt;ulink linkType="Reference" linkID="1327731"&gt;1327731&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="7">&lt;para&gt;As a type I anti-CD20 antibody, Rituxan has demonstrated 5- to 100-fold less activity in inducing antibody-dependent cytotoxicity compared with type II anti-CD20 antibodies such as &lt;ulink linkType="Drug" linkID="53227"&gt;obinutuzumab&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="42299"&gt;ofatumumab&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1322753"&gt;1322753&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1334508"&gt;1334508&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="8">&lt;para&gt;Principal patents with claims to Rituxan or its use expired in the US between April 2015 and December 2018, and expired in the rest of the world in 2013 [&lt;ulink linkType="Reference" linkID="1079336"&gt;1079336&lt;/ulink&gt;], [&lt;ulink linkType="Patent" linkID="IN2689773"&gt;US-05736137&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="9">&lt;para&gt;The first biosimilars (&lt;ulink linkType="Drug" linkID="78947"&gt;Truxima&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="79391"&gt;Rixathon&lt;/ulink&gt;) were approved in the EU in 1H17 and first launch occurred in the UK in April 2017; the first biosimilar (Rixathon) was launched in Japan in January 2018; in November 2018, Truxima was approved in the US but without including CLL in the label [&lt;ulink linkType="Reference" linkID="1870353"&gt;1870353&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1938617"&gt;1938617&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1938617"&gt;1938617&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1961042"&gt;1961042&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1942091"&gt;1942091&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1998025"&gt;1998025&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2099579"&gt;2099579&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2099781"&gt;2099781&lt;/ulink&gt;]&lt;/para&gt;</Weakness></Weaknesses><Opportunities><Opportunity name="Opportunity" sortOrder="1">&lt;para&gt;NHL is the most common form of blood cancer and CLL is the most common form of adult leukemia [&lt;ulink linkType="Reference" linkID="1076167"&gt;1076167&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1322761"&gt;1322761&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="10">&lt;para&gt;Monotherapy position in aggressive lymphoma; there has been a lack of progress with therapeutic options for DLBCL since Rituxan was introduced [&lt;ulink linkType="Reference" linkID="1323052"&gt;1323052&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="2">&lt;para&gt;Indolent NHL is a treatable disease with survival in excess of 10 years, therefore patients are likely to receive multiple lines of therapy [&lt;ulink linkType="Reference" linkID="1322761"&gt;1322761&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="3">&lt;para&gt;Achieved high penetration in NHL and CLL and works so well that it may be challenging for other agents to overcome such a formidable competitor [&lt;ulink linkType="Reference" linkID="968368"&gt;968368&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1074873"&gt;1074873&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1323052"&gt;1323052&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="4">&lt;para&gt;Uptake in treatment-naive patients with CLL is a key Rituxan growth driver; the vast majority of CLL patients are expected to receive at least one course of Rituxan therapy at some point in their treatment [&lt;ulink linkType="Reference" linkID="1072739"&gt;1072739&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1076127"&gt;1076127&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1076167"&gt;1076167&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="5">&lt;para&gt;Despite the threat of numerous biosimilars in development, the clinical adoption of these remains uncertain, and physicians may be very hesitant to use these at any price unless the clinical data were compelling [&lt;ulink linkType="Reference" linkID="1657958"&gt;1657958&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="6">&lt;para&gt;Increased use in the maintenance setting in NHL is a key growth driver; leverage the compelling PRIMA data in this setting [&lt;ulink linkType="Reference" linkID="1102294"&gt;1102294&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1143102"&gt;1143102&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="7">&lt;para&gt;&lt;ulink linkType="Company" linkID="19446"&gt;Roche&lt;/ulink&gt;&amp;apos;s Rituxan follow-up &lt;ulink linkType="Drug" linkID="53227"&gt;Gazyva&lt;/ulink&gt; failed to demonstrate overall survival superiority to Rituxan in DLBCL and the product was discontinued in this setting, thus losses to this competitor will be lessened outside of CLL [&lt;ulink linkType="Reference" linkID="1780631"&gt;1780631&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1781069"&gt;1781069&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1867297"&gt;1867297&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="8">&lt;para&gt;Also, potential to drive sales from combination use with &lt;ulink linkType="Drug" linkID="27572"&gt;Revlimid&lt;/ulink&gt; or Gazyva in CLL, particularly as physicians become more familiar with Gazyva [&lt;ulink linkType="Reference" linkID="1244399"&gt;1244399&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1322755"&gt;1322755&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="9">&lt;para&gt;Drive use of the subcutaneous formulation for patients with follicular lymphoma that will improve patient convenience and safety; a more rapid 90-min infusion schedule has also been approved in the US which could also be a meaningful differentiator [&lt;ulink linkType="Reference" linkID="1364417"&gt;1364417&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1540512"&gt;1540512&lt;/ulink&gt;]&lt;/para&gt;</Opportunity></Opportunities><Threats><Threat name="Threat" sortOrder="1">&lt;para&gt;Losses to biosimilars in the EU, Japan and in the US; there are numerous biosimilars in development and losses could be significant [&lt;ulink linkType="Reference" linkID="1938617"&gt;1938617&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1938617"&gt;1938617&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1961042"&gt;1961042&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1942091"&gt;1942091&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1998025"&gt;1998025&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2099579"&gt;2099579&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2099781"&gt;2099781&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="10">&lt;para&gt;&lt;ulink linkType="Drug" linkID="47000"&gt;Treanda&lt;/ulink&gt;, which is a maintstay in CLL and which also has compelling efficacy in the refractory NHL setting; the drug is also viewed favorably due to its twice 3-weekly dosing and also shows activity in first-line NHL. Treanda may also be vulnerable to generic competition in the short term [&lt;ulink linkType="Reference" linkID="1074873"&gt;1074873&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1167791"&gt;1167791&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="11">&lt;para&gt;&lt;ulink linkType="Drug" linkID="34140"&gt;Blinatumomab&lt;/ulink&gt; is also advancing in NHL and is currently in phase II/III [&lt;ulink linkType="Reference" linkID="1900450"&gt;1900450&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1945000"&gt;1945000&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="12">&lt;para&gt;The generic CHOP chemotherapy regimen in indolent NHL [&lt;ulink linkType="Reference" linkID="1278644"&gt;1278644&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="13">&lt;para&gt;&lt;ulink linkType="Company" linkID="16450"&gt;Gilead&lt;/ulink&gt;&amp;apos;s &lt;ulink linkType="Drug" linkID="48319"&gt;Zydelig&lt;/ulink&gt;, which has been launched in the US for relapsed CLL and indolent NHL, has good response rates and duration of action [&lt;ulink linkType="Reference" linkID="1604600"&gt;1604600&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="14">&lt;para&gt;&lt;ulink linkType="Company" linkID="1058061"&gt;Verastem&lt;/ulink&gt;&amp;apos;s &lt;ulink linkType="Drug" linkID="62418"&gt;duvelisib&lt;/ulink&gt;, which has been filed for approval in the US for CLL, showed superiority in FPS and ORR over Arzerra in a phase III study (DUO) [&lt;ulink linkType="Reference" linkID="1959381"&gt;1959381&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="15">&lt;para&gt;&lt;ulink linkType="Drug" linkID="55237"&gt;Imbruvica&lt;/ulink&gt;, which was has become a new cornerstone in CLL therapy with a broad label, impressive activity in all patient risk groups and stronger data head-to-head versus Arzerra [&lt;ulink linkType="Reference" linkID="1524325"&gt;1524325&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1618402"&gt;1618402&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="16">&lt;para&gt;&lt;ulink linkType="Company" linkID="31093"&gt;TG Therapeutics&lt;/ulink&gt;&amp;apos; &lt;ulink linkType="Drug" linkID="56236"&gt;ublituximab&lt;/ulink&gt;, which is in phase III development for CLL al follicular lymphoma [&lt;ulink linkType="Reference" linkID="1971178"&gt;1971178&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="17">&lt;para&gt;Novartis&amp;apos; CAR T-cell therapy &lt;ulink linkType="Drug" linkID="79749"&gt;Kymriah&lt;/ulink&gt; is advancing in CLL; the company plans to file in 2021 [&lt;ulink linkType="Reference" linkID="2004756"&gt;2004756&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="18">&lt;para&gt;&lt;b&gt;Last updated on March 19, 2019&lt;/b&gt;&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="2">&lt;para&gt;Despite the leadership position in CLL, areas of unmet need remain in certain patients, such as the elderly, patients with comorbidities or patients with del17P mutations, and development of more effective treatments in these settings would see loss of market share [&lt;ulink linkType="Reference" linkID="1657963"&gt;1657963&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1657964"&gt;1657964&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="3">&lt;para&gt;CLL is a relatively modest market, with only about 21,000 patients diagnosed in the US each year. Indolent B-cell NHL is a larger market, but still restricted to 50,000 to 60,000 patients in the US per year [&lt;ulink linkType="Reference" linkID="1792499"&gt;1792499&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1278646"&gt;1278646&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="4">&lt;para&gt;Roche&amp;apos;s Rituxan follow-up Gazyva, which has shown superiority to Rituxan in phase III treatment-naive CLL, and which was approved in CLL in 2013 and FL in 2016; Roche also pushed the switch to Gazyva ahead of biosimilar entry [&lt;ulink linkType="Reference" linkID="1495240"&gt;1495240&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="5">&lt;para&gt;Gazyva may also see greater use in the front-line setting in elderly CLL patients, who may not tolerate the more commonly used Rituxan/cyclophosphamide/Fludara regimen; elderly patients represent 20% of new CLL diagnoses [&lt;ulink linkType="Reference" linkID="1278642"&gt;1278642&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="6">&lt;para&gt;&lt;ulink linkType="Drug" linkID="70895"&gt;Venclexta&lt;/ulink&gt;, which was approved in April 2016 and which looks a strong contender in CLL with 17p deletion [&lt;ulink linkType="Reference" linkID="1750582"&gt;1750582&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="7">&lt;para&gt;Competition in refractory CLL from &lt;ulink linkType="Company" linkID="26469"&gt;Genmab&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="23137"&gt;Novartis&lt;/ulink&gt;&amp;apos; &lt;ulink linkType="Drug" linkID="42299"&gt;Arzerra&lt;/ulink&gt;, which is also an anti-CD20 mAb competitor, and it is advancing phase III development in NHL with a filing expected in 2020 [&lt;ulink linkType="Reference" linkID="2004756"&gt;2004756&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="8">&lt;para&gt;&lt;ulink linkType="Drug" linkID="2716"&gt;Campath&lt;/ulink&gt;, which is notable for its activity in patients with poor prognostic cytogenetic abnormalities who are otherwise resistant to chemotherapies [&lt;ulink linkType="Reference" linkID="408341"&gt;408341&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1051917"&gt;1051917&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="9">&lt;para&gt;Low-dose &lt;ulink linkType="Drug" linkID="27572"&gt;Revlimid&lt;/ulink&gt;, which may have potential to become key competitor in the aggressive and refractory indolent NHL setting, given that it is dosed orally and has a unique mechanism of action [&lt;ulink linkType="Reference" linkID="643572"&gt;643572&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="969197"&gt;969197&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="979944"&gt;979944&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106014"&gt;1106014&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106013"&gt;1106013&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1063068"&gt;1063068&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1278651"&gt;1278651&lt;/ulink&gt;]&lt;/para&gt;</Threat></Threats></SWOT><SWOT><Class>Rheumatoid arthritis and associated immunological disorders</Class><Strengths><Strength name="Strength" sortOrder="1">&lt;para&gt;Differentiated mechanism of action from the TNF inhibitor class of biologicals, with an action on B cells. Efficacious in patients not responding to TNF inhibitors [&lt;ulink linkType="Reference" linkID="1480951"&gt;1480951&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="2">&lt;para&gt;Significant efficacy in inadequate responders to methotrexate (MTX) in the REFLEX study in rheumatoid arthritis (RA); 51% of patients treated with Rituxan plus MTX achieved ACR20 compared with 18% of patients treated with MTX alone [&lt;ulink linkType="Reference" linkID="1480951"&gt;1480951&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1777275"&gt;1777275&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="3">&lt;para&gt;Labeled claims supporting improvement in physical function and inhibition of progression of joint damage; mean change in Genant-modified Sharp score was 1 compared with 2.31 in the Rituxan group at week 56, and there were also significant differences observed in changes of erosion score and joint space narrowing [&lt;ulink linkType="Reference" linkID="1480951"&gt;1480951&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1777275"&gt;1777275&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="4">&lt;para&gt;Consistent safety profile, with no increase in malignancy or infections [&lt;ulink linkType="Reference" linkID="1777275"&gt;1777275&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="5">&lt;para&gt;Unique dosing profile for RA; one course of treatment consists of two iv infusions 2 weeks apart, every 6 months, potentially allowing for only four infusions over a 1-year period [&lt;ulink linkType="Reference" linkID="1480951"&gt;1480951&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="6">&lt;para&gt;Does not require reconstitution unlike &lt;ulink linkType="Drug" linkID="6850"&gt;Remicade&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2888"&gt;Orencia&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1480951"&gt;1480951&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1168570"&gt;1168570&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1478576"&gt;1478576&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="7">&lt;para&gt;The only FDA-approved therapy for granulomatosis with polyangiitis and microscopic polyangiitis, based on the RAVE study showing non-inferiority to the standard of care cyclophosphamide in inducing disease remission at 6 months [&lt;ulink linkType="Reference" linkID="1185238"&gt;1185238&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1777275"&gt;1777275&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="8">&lt;para&gt;The first approved therapy for pempigus vulgaris in 60 years; 90% of patients&amp;apos; pemphigus was controlled at 2 years in the Ritux-3 study compared with 28% for corticosteroids [&lt;ulink linkType="Reference" linkID="2042593"&gt;2042593&lt;/ulink&gt;]&lt;/para&gt;</Strength></Strengths><Weaknesses><Weakness name="Weakness" sortOrder="1">&lt;para&gt;Relatively limited label for RA; only approved in combination with MTX in patients who have failed TNF inhibitors, unlike Orencia and &lt;ulink linkType="Drug" linkID="6259"&gt;Actemra&lt;/ulink&gt; which can be used with or without MTX [&lt;ulink linkType="Reference" linkID="1480951"&gt;1480951&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="645239"&gt;645239&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1168570"&gt;1168570&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="10">&lt;para&gt;The first biosimilars (&lt;ulink linkType="Drug" linkID="78947"&gt;Truxima&lt;/ulink&gt; and Rixathon) were approved in the EU in 1H17 and first launch occurred in the UK in April 2017; biosimilar filings were submitted in the in 3Q17 [&lt;ulink linkType="Reference" linkID="1870353"&gt;1870353&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1938617"&gt;1938617&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1938617"&gt;1938617&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1961042"&gt;1961042&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1942091"&gt;1942091&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="2">&lt;para&gt;The FDA declined to approve Rituxan for earlier RA use in DMARD non-responders due to a risk of progressive multifocal leukoencephalopathy (PML) [&lt;ulink linkType="Reference" linkID="1050300"&gt;1050300&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="3">&lt;para&gt;The label carries a boxed warning regarding the risk of fatal infusion reactions, severe mucocutaneous reactions, the risk of hepatitis B virus reactivation with fulminant hepatitis and hepatic failure resulting in death and PML, including fatal PML [&lt;ulink linkType="Reference" linkID="1480951"&gt;1480951&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="4">&lt;para&gt;Further warnings on label regarding tumor lysis syndrome, cardiac arrhythmias, angina, bowel obstruction and perforation, and cytopenias requiring blood count monitoring [&lt;ulink linkType="Reference" linkID="1480951"&gt;1480951&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="5">&lt;para&gt;Most common adverse reactions in RA clinical trials (&amp;gt;/= 10%) were upper respiratory tract infection, nasopharyngitis, urinary tract infection and bronchitis [&lt;ulink linkType="Reference" linkID="1480951"&gt;1480951&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="6">&lt;para&gt;Requires premedication due to the risk of severe, fatal infusion reactions, unlike competitor infusion therapies Orencia and Actemra [&lt;ulink linkType="Reference" linkID="1478292"&gt;1478292&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1478295"&gt;1478295&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1168570"&gt;1168570&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="7">&lt;para&gt;Inconvenience of long infusion time, which generally takes 4 to 6 h, unlike 30-min infusion for Orencia and Simponi Aria [&lt;ulink linkType="Reference" linkID="1480999"&gt;1480999&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="645239"&gt;645239&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1480532"&gt;1480532&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="8">&lt;para&gt;Lack of subcutaneous formulation places Rituxan at a convenience disadvantage compared with self-injectable biologicals [&lt;ulink linkType="Reference" linkID="1480951"&gt;1480951&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="9">&lt;para&gt;Principal patents with claims to Rituxan or its use expired in the US in April 2015, and began to expire in the rest of the world in 2013 [&lt;ulink linkType="Reference" linkID="1079336"&gt;1079336&lt;/ulink&gt;], [&lt;ulink linkType="Patent" linkID="IN2689773"&gt;US-05736137&lt;/ulink&gt;]&lt;/para&gt;</Weakness></Weaknesses><Opportunities><Opportunity name="Opportunity" sortOrder="1">&lt;para&gt;RA is a chronic, incurable disease requiring long-term treatment; RA affects up to 1.0% of the global population [&lt;ulink linkType="Reference" linkID="1777233"&gt;1777233&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1777234"&gt;1777234&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="2">&lt;para&gt;Continued uptake in the substantial portion of RA patients (20 to 40%) who fail anti-TNF therapy [&lt;ulink linkType="Reference" linkID="1777234"&gt;1777234&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1382880"&gt;1382880&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="3">&lt;para&gt;American College of Rheumatology (ACR) guidelines recommend non-TNF biologicals as an alternative to TNF inhibitors post MTX in established RA. Guidelines recommend the use of non-TNF biologicals, such as Rituxan, over TNF inhibitors in patients with heart failure [&lt;ulink linkType="Reference" linkID="1777235"&gt;1777235&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="4">&lt;para&gt;Expansion in rapidly growing biological markets in Brazil, Japan, China and Russia [&lt;ulink linkType="Reference" linkID="1777255"&gt;1777255&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="5">&lt;para&gt;Leverage status as first ever approved therapy for the rare blood vessel diseases granulomatosis with polyangiitis and microscopic polyangiitis, as well as approval in pemphigus vulgaris [&lt;ulink linkType="Reference" linkID="1185238"&gt;1185238&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1777275"&gt;1777275&lt;/ulink&gt;]&lt;/para&gt;</Opportunity></Opportunities><Threats><Threat name="Threat" sortOrder="1">&lt;para&gt;Sales may be limited by the risk of PML; physicians may also be concerned about switching patients from Rituxan to other drugs during a period of B-cell suppression, and non-responding patients may face a long washout period to avoid further immunosuppression with two biologics [&lt;ulink linkType="Reference" linkID="2125098"&gt;2125098&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="10">&lt;para&gt;Patient preference for subcutaneously administered RA therapies; subcutaneous formulations represent approximately 70% of the global RA biologics market [&lt;ulink linkType="Reference" linkID="1399468"&gt;1399468&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="11">&lt;para&gt;Higher prices and payor-mandated prescribing barriers associated with biologicals compared with topical and oral therapies may limit uptake. High cost and injectable route of administration for biologicals are also barriers to use in developing countries [&lt;ulink linkType="Reference" linkID="1385395"&gt;1385395&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1385927"&gt;1385927&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1385377"&gt;1385377&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1384831"&gt;1384831&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1111720"&gt;1111720&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="12">&lt;para&gt;MTX is cheap, has a long history of use and high level of physician familiarity and is recommended by clinical guidelines as the first-line agent of choice for moderate-to-severe psoriasis and initial RA therapy [&lt;ulink linkType="Reference" linkID="1777235"&gt;1777235&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1777252"&gt;1777252&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1384285"&gt;1384285&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1734151"&gt;1734151&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="13">&lt;para&gt;Biologic pipeline candidates for RA aimed at novel targets, such as &lt;ulink linkType="Drug" linkID="94235"&gt;PF-06651600&lt;/ulink&gt;, the first oral JAK3 inhibitor, &lt;ulink linkType="Drug" linkID="53625"&gt;otilimab&lt;/ulink&gt;, a granulocyte macrophage colony-stimulating factor, &lt;ulink linkType="Drug" linkID="63511"&gt;NI-0101&lt;/ulink&gt;, an anti-TLR4 antibody, and bispecific therapeutics such as &lt;ulink linkType="Drug" linkID="81491"&gt;MT-6194&lt;/ulink&gt;, a bispecific anti-IL-6/IL-17A antibody [&lt;ulink linkType="Reference" linkID="1878285"&gt;1878285&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2084158"&gt;2084158&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1709240"&gt;1709240&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2124673"&gt;2124673&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="14">&lt;para&gt;&lt;b&gt;Last updated on March 01, 2019&lt;/b&gt;&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="2">&lt;para&gt;Losses to biosimilars in the EU, and in the short term in the US; while several biosimilar developers in the US received Complete Response letters for their initial filings, approval is expected in 2019 [&lt;ulink linkType="Reference" linkID="1938617"&gt;1938617&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1938617"&gt;1938617&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1961042"&gt;1961042&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1942091"&gt;1942091&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="3">&lt;para&gt;Biosimilar entry for the anti TNF inhibitors, which could affect sales; the first biosimilars of Remicade (&lt;ulink linkType="Drug" linkID="78759"&gt;Inflectra&lt;/ulink&gt;/Remsima) entered in the EU in late 2013 and US in late 2016; Enbrel biosimilars were approved and launched in the EU in early 2016 (&lt;ulink linkType="Drug" linkID="85594"&gt;Benepali&lt;/ulink&gt;) and approved in the US in August 2016 (&lt;ulink linkType="Drug" linkID="85879"&gt;Erelzi&lt;/ulink&gt;), and the first Humira biosimilar was launched in the EU in October 2018 with launch in the US expected in 2022/2023 [&lt;ulink linkType="Reference" linkID="1749066"&gt;1749066&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1895152"&gt;1895152&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1903902"&gt;1903902&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1792311"&gt;1792311&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1900450"&gt;1900450&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1901564"&gt;1901564&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1956171"&gt;1956171&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="4">&lt;para&gt;Biosimilars may be formally addressed in future treatment guideline updates, which could increase use; broader discussions to reduce drug spending in the US are also taking place, which could include FDA incentives for better biosimilar interchangeability – the FDA first published a Biosimilar Action Plan in February 2018 [&lt;ulink linkType="Reference" linkID="2124390"&gt;2124390&lt;/ulink&gt;]    &lt;/para&gt;</Threat><Threat name="Threat" sortOrder="5">&lt;para&gt;Direct competition from TNF inhibitors with overlapping labels; there are now five anti-TNFs approved (&lt;ulink linkType="Drug" linkID="14163"&gt;Humira&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="4567"&gt;Enbrel&lt;/ulink&gt;, Remicade, &lt;ulink linkType="Drug" linkID="42857"&gt;Simponi&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="21138"&gt;Cimzia&lt;/ulink&gt;), which are well entrenched in RA and are usually prescribed as first- and second-line biological agents after MTX failure ahead of newer therapies [&lt;ulink linkType="Reference" linkID="1777251"&gt;1777251&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1777252"&gt;1777252&lt;/ulink&gt;]   &lt;/para&gt;</Threat><Threat name="Threat" sortOrder="6">&lt;para&gt;Humira in particular is a well-entrenched brand with over 15 years on the market and stable blockbuster sales, currently ranked as the top-selling anti-TNF medication worldwide. Humira has the broadest label of the TNF inhibitors and is the preferred therapy by payors for rheumatology [&lt;ulink linkType="Reference" linkID="1391145"&gt;1391145&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1736488"&gt;1736488&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1477322"&gt;1477322&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1775351"&gt;1775351&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="7">&lt;para&gt;Enbrel is the most prescribed biological agent in biological-naive RA patients [&lt;ulink linkType="Reference" linkID="1478373"&gt;1478373&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1730787"&gt;1730787&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="8">&lt;para&gt;Competition from other non-TNF biologicals, such as Actemra and Orencia, which are both available as intravenous and subcutaneous formulations and are alternative treatment options after failed TNF inhibitor therapy [&lt;ulink linkType="Reference" linkID="1777251"&gt;1777251&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1777252"&gt;1777252&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="9">&lt;para&gt;Newer non-TNF options are also now available, such as the JAK inhibitors &lt;ulink linkType="Drug" linkID="45499"&gt;Xeljanz&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="59098"&gt;Olumiant&lt;/ulink&gt;, the only oral options outside of the anti-TNF class. Xeljanz has demonstrated comparable efficacy to Humira in RA and Olumiant has shown superior efficacy versus Humira, and both drugs have labels for MTX-failures. There is also potential future competition in the class including &lt;ulink linkType="Company" linkID="1072507"&gt;AbbVie&lt;/ulink&gt;&amp;apos;s &lt;ulink linkType="Drug" linkID="74726"&gt;upadacitinib&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="16450"&gt;Gilead&lt;/ulink&gt;&amp;apos;s &lt;ulink linkType="Drug" linkID="67629"&gt;filgotinib&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1314597"&gt;1314597&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1338340"&gt;1338340&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1702963"&gt;1702963&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2125087"&gt;2125087&lt;/ulink&gt;]&lt;/para&gt;</Threat></Threats></SWOT></SWOTs></drugSwotsOutput>